Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Relypsa, Galenica, Fresenius deal

    Relypsa Inc. (NASDAQ:RLYP), Redwood City, Calif. Galenica Ltd. (SIX:GALN), Bern, Switzerland Fresenius SE & Co. KGaA (Xetra:FRE;OTCQX:FSNUY), Bad Homburg, Germany Business: Endocrine/Metabolic Relypsa granted Vifor …

    Published on 9/28/2015
  • Relypsa, Sanofi deal

    Relypsa Inc. (NASDAQ:RLYP), Redwood City, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Endocrine/Metabolic Relypsa granted Sanofi rights to co-promote patiromer for oral suspension in the U.S. for two …

    Published on 9/28/2015
  • Syndax, Roche, Genentech deal

    Syndax Pharmaceuticals Inc., Waltham, Mass. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Genentech Inc., South San Francisco, Calif. Business: Cancer Syndax and Roches Genentech unit partnered to evaluate Syndaxs …

    Published on 9/28/2015
  • The Chao Center, Rodelis Therapeutics deal

    The Chao Center for Industrial Pharmacy & Contract Manufacturing, West Lafayette, Ind. Rodelis Therapeutics, Alpharetta, Ga. Business: Infectious Nonprofit Chao Center reacquired rights from Rodelis to Seromycin …

    Published on 9/28/2015
  • The Gores Group, Mallinckrodt deal

    The Gores Group LLC, Beverly Hills, Calif. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Cancer Mallinckrodt will acquire Therakos Inc. from investment firm Gores for $1.3 billion in cash in a deal slated to …

    Published on 9/28/2015
  • UCB, Zai Laboratory deal

    UCB Group (Euronext:UCB), Brussels, Belgium Zai Laboratory Ltd., Shanghai, China Business: Autoimmune, Transplant UCB granted Zai exclusive, worldwide rights to develop and commercialize an undisclosed preclinical mAb. …

    Published on 9/28/2015
  • UCSD, PsychoGenics deal

    University of California San Diego, La Jolla, Calif. PsychoGenics Inc., Tarrytown, N.Y. Business: Neurology The universitys school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) …

    Published on 9/28/2015
  • University Health Network, Sernova deal

    University Health Network, Toronto, Ontario Sernova Corp. (TSX-V:SVA;OTCQB:SEOVF), London, Ontario Business: Gene/Cell therapy, Endocrine/Metabolic The University Health Network granted Sernova exclusive, worldwide …

    Published on 9/28/2015
  • University of Cambridge, DefiniGEN deal

    University of Cambridge, Cambridge, U.K. DefiniGEN Ltd., Cambridge, U.K. Business: Gene/Cell therapy The university granted DefiniGEN rights to develop and commercialize lung stem cell technology, which uses induced …

    Published on 9/28/2015
  • University of Minnesota, Oxis deal

    University of Minnesota, Minneapolis, Minn. Oxis International Inc. (OTCQB:OXIS;Euronext:OXI), Beverly Hills, Calif. Business: Cancer Two researchers at the university granted Oxis exclusive, worldwide rights to develop…

    Published on 9/28/2015
  • Viamet, Mycoses Study Group Education and Research Consortium deal

    Viamet Pharmaceuticals Inc., Durham, N.C. Mycoses Study Group Education and Research Consortium, Birmingham, Ala. Business: Infectious Viamet and the Mycoses Study Group Education & Research Consortium (MSGERC) …

    Published on 9/28/2015
  • Advaxis, Knight Therapeutics deal

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Business: Cancer Advaxis granted Knight exclusive rights to commercialize Advaxis product portfolio and future products …

    Published on 9/21/2015
  • Ajou University, MiracleIN deal

    Ajou University, Suwon, South Korea MiracleIN Co. Ltd., Incheon, South Korea Business: Infectious MiracleIN and the universitys college of pharmacy partnered to develop drugs to prevent infectious diseases, including …

    Published on 9/21/2015
  • Amgen, NantWorks deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. NantWorks LLC, Los Angeles, Calif. Business: Cancer Amgen granted NantWorks NantPharma LLC subsidiary exclusive, worldwide rights to develop and commercialize AMG 337, …

    Published on 9/21/2015
  • Aptinyx, Allergan deal

    Aptinyx Inc., Chicago, Ill. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Neurology Newco Aptinyx and Allergan will collaborate on the discovery and preclinical development of oral small molecule NMDA receptor …

    Published on 9/21/2015
  • Berg, University of Miami deal

    Berg LLC, Farmingham, Mass. University of Miami, Coral Gables, Fla. Business: Diagnostic Berg and the university partnered to identify biomarkers for cardiac disease to improve testing capabilities and patient outcomes.…

    Published on 9/21/2015
  • BioMarin, Medivation deal

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Business: Cancer Medivation will purchase exclusive, worldwide rights to talazoparib from BioMarin. …

    Published on 9/21/2015
  • Boehringer Ingelheim, Circuit Therapeutics deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Circuit Therapeutics Inc., Menlo Park, Calif. Business: Endocrine/Metabolic Circuit and Boehringer partnered to use Circuits optogenetics technology to identify and select …

    Published on 9/21/2015
  • Burning Rock Biotech, Illumina deal

    Burning Rock Biotech, Guangzhou, China Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Business: Diagnostic The companies partnered to develop an cancer molecular diagnostic kit for the Chinese market. The kit will …

    Published on 9/21/2015
  • Celgene, Recombinant Antibody Network deal

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Recombinant Antibody Network, San Francisco, Calif. Business: Cancer Celgene and the Recombinant Antibody Network (RAN) will develop next-generation antibody-based cancer …

    Published on 9/21/2015
  • Cord Blood Registry, AMAG Pharmaceuticals deal

    Cord Blood Registry, San Bruno, Calif. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Business: Neurology AMAG completed its acquisition of stem cell company Cord Blood Registry for $700 million in cash from …

    Published on 9/21/2015
  • Dezima, Amgen deal

    Dezima Pharma B.V., Naarden, the Netherlands Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Endocrine/Metabolic Amgen will acquire Dezima for $300 million up front and up to $1.3 billion in milestones, plus …

    Published on 9/21/2015
  • Genmab, Novo Nordisk deal

    Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark Business: Antibodies Genmab granted Novo exclusive, worldwide rights to use Genmabs DuoBody technology to …

    Published on 9/21/2015
  • Immune Design, Merck deal

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Immune and Merck partnered to evaluate Mercks melanoma drug Keytruda pembrolizumab with Immunes LV305 for …

    Published on 9/21/2015
  • ImmunID, Scancell deal

    ImmunID S.A.S., Grenoble, France Scancell Holdings plc (LSE:SCLP;Xetra:SCP), Nottingham, U.K. Business: Pharmacogenetics The companies will use ImmunIDs ImmunTraCkeR test to predict which patients will respond to …

    Published on 9/21/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993